Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
18683-91-5
Molecular formula
C13H18Br2N2O
Molecular weight
378.1 g/mol
Drug class
Mucolyticsecretolytic and mucokinetic agent (bromhexine metabolite)
Mechanism of action
The precise mechanism is not fully elucidated. Ambroxol increases serous respiratory secretion, stimulates ciliary activity and mucociliary clearance, and activates pulmonary surfactant production, helping reduce mucus viscosity and facilitate expectoration.
Indications / reported uses
Expectorant use in acute and chronic respiratory conditions with abnormal viscid mucus, where authorised
Lozenge formulations may be used for sore throat; injectable uses and indications differ by product and jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Ambroxol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ambroxol Permitted Daily Exposure (PDE) report (the Ambroxol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ambroxol Occupational Exposure Limit (OEL) report (the Ambroxol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.